Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Original Article from The New England Journal of Medicine — Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Related Articles
The Frontiers Symposium on Transformation in Cancer Care Delivery
Frontiers Symposium on Transformation in Cancer Care Delivery Huntsman Cancer Institute
Why Donate To The Hope Foundation? – SWOG Cancer Research Network
Why Donate to the Hope Foundation? Simple, all donations support the science, education and patients of the SWOG Cancer Research Network.
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer | NEJM
Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder canc…
Urology, cancer Summit
The Second International Urology Cancer Summit is a free and independent educational opportunity open to everyone involved in caring for patients with urologic cancers.
Urology, cancer Summit
The Second International Urology Cancer Summit is a free and independent educational opportunity open to everyone involved in caring for patients with urologic cancers.
Urology, cancer Summit
The Second International Urology Cancer Summit is a free and independent educational opportunity open to everyone involved in caring for patients with urologic cancers.
ESMO Congress 2024 | OncologyPRO
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
ESMO Congress 2024 | OncologyPRO
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma | Journal of Clinical Oncology
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published…